70,000 Cancer Patients Sue GSK and Other Pharma Giants, Zantac Stomach Drug Cloud Rises Again!
The Delaware Supreme Court announced on Tuesday that it would rehear an appeal brought by GlaxoSmithKline (GSK) and several other pharmaceutical companies. The companies are trying to end more than 70,000 lawsuits over a link between Zantac, the stomach drug they once sold, and cancer. GSK, Pfizer, Sanofi and Boehringer Ingelheim had asked to overturn a lower court decision that allowed the plaintiffs to present expert evidence related to cancer. The drug companies maintain that the evidence lacks scientific support and that without it it would be difficult to proceed.
In Delaware, Zantac-related lawsuits have yet to go to trial or reach a final decision. The state's highest judicial body only deliberates on appeals in certain circumstances before making a final decision. Glaxosmithkline (GSK) said in its official statement that it was pleased by the Supreme Court's decision that the case was of an exceptional nature. The plaintiffs' legal representatives, Attorney Jennifer Moore and Attorney Brent Wisner, issued a joint statement expressing firm confidence that the Supreme Court would uphold the trial court's decision. Business groups, including the U.S. Chamber of Commerce, have petitioned the Supreme Court to take up the case, expressing concern about the possible consequences of the lower court's ruling, which they fear will make Delaware a hub for mass tort lawsuits.
After being approved by U.S. regulators in 1983, Zantac became a top-selling drug in 1988 and ranks among the billion-dollar drugs in annual sales. The four companies, all of which sold the drug at various times, are facing thousands of lawsuits. The lawsuit originated in 2020, when the U.S. Food and Drug Administration (FDA) asked manufacturers to pull Zantac from the market because its active ingredient, ranitidine, could be converted to NDMA, a carcinogen. Currently, three Zantac cases have gone to trial in Illinois, two of which have been decided in favor of the defendants and one is pending.
2026-10-25
Trade Alert
Delivering the latest product trends and industry news straight to your inbox.
(We'll never share your email address with a third-party.)
Related News
-
BASF Commits to Safeguarding Jobs at the Ludwigshafen Site Through 2028 with Multi-Billion-Euro Investments
-
“Strategic Amputation” or “Phoenix Rebirth”? AkzoNobel’s Global Retreat and a $25 Billion Gamble
-
Henkel Plans to Acquire Swiss Adhesive Specialist ATP Adhesive Systems, Expanding Its Sustainable Tape Portfolio
-
When BASF Lets Agriculture Fly Solo: A Capital Repricing of Scale and Ambition
-
Production Down 6%, Profits Cut by $3.7 Billion: Middle East Conflict Hits ExxonMobil Hard
-
Europe’s Chemical Industry in the Ice Age: Profits Evaporating, Plants Shutting Down, Capital Fleeing—A Systemic Collapse Is Underway
-
Huntsman’s Rotterdam Plant Hit by Unexpected Shutdown, Q4 EBITDA Takes a $10M Hit
-
BASF, Sinopec Forge Green Alliance to Power Nanjing Site with Certified Bio-Methane
-
Univar Solutions Expands Partnership with American Distilling in EMEA to Strengthen Natural Specialty Ingredients Distribution Network
-
Novo Nordisk Enters High-Stakes Bidding War with Pfizer for Metsera
Recommend Reading
-
BASF Partners with Sinopec to Accelerate Application of Biomethane at Nanjing
-
Behind Starbucks China’s Ownership Change: The Race for Localization and Efficiency
-
Is Evonik’s Massive Global Expansion of Hydroxyl-Terminated Polybutadiene (HTPB) a Technological Ambition — or a Geopolitical Gamble?
-
Wanhua’s Counter-Cyclical Expansion: A Gamble or a Strategic Move for the Next Cycle?
-
Record Net Profit, Yet “Joining Forces” with a Rival? Axalta Drops a Final Trump Card Before the Merger
-
Business Society October 15, 2026 Styrene Trend Analysis: Weakness and Volatility
-
Business Society October 15, 2026 DOP Trend Analysis: Moderately Bearish
-
Business Society October 15, 2026 Hydrogen Peroxide Trend Analysis: Volatility
-
Business Society October 15, 2026 Lithium Carbonate Trend Analysis: Clear Downtrend
-
Business Society October 14, 2026 Hydrogen Peroxide Trend Analysis: Volatility
- Hot Searches
- nsi 189 price
- where to buy cerebrolysin peptide
- retatrutide 10mg where to buy
- price of retatrutide
- semaglutide research peptide for sale
- price of sodium sulphate
- purchase red phosphorus
- sodium hydrogen sulfide
- ehtyl acetate sds
- bioglutide for sale
- retatrutide peptide buy usa price
- chemical marketplace